S15 Ep34: Cases and Conversations™: Transforming Small Cell Lung Cancer Treatment Through Emerging Evidence and Expert Insights
In this podcast, experts Charles M. Rudin, MD, PhD; Anne Chiang, MD, PhD, FASCO; and Jacob M. Sands, MD; discuss immune checkpoint inhibitor–based strategies in limited-stage (LS) and extensive-stage (ES) small cell lung cancer (SCLC), practical considerations for integrating novel agents such as tarlatamab and lurbinectedin, and the emerging role of antibody-drug conjugates in the treatment of ES-SCLC.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.